Thelansis

Advanced and Metastatic Endometrial Carcinoma Market Outlook Thelansis’s “Advanced and Metastatic Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Whic...

Advanced and Metastatic Endometrial Carcinoma Market Outlook Thelansis’s “Advanced and Metastatic Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Advanced and Metastatic Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Advanced and Metastatic Endometrial Carcinoma Overview Endometrial carcinoma (EC) OR Uterine serous carcinoma (USC) is the most common gynecologic malignancy and will be encountered by almost every gynecologist. The most common symptoms are abnormal uterine bleeding and vaginal discharge. Patients with advanced disease may have symptoms similar to those seen with advance...

 Endometrial carcinoma (EC) OR Uterine serous carcinoma (USC) is the most common gynecologic malignancy and will be encountered by almost every gynecologist. The most common symptoms are abnormal uterine bleeding and vaginal discharge. Patients with advanced disease may have symptoms similar to those seen with advanced ovarian cancer, such as abdominal or pelvic pain, abdominal distension, early satiety, or a change in bowel or bladder function. Prolonged unopposed estrogen exposure is associated with most type I endometrial cancers. Estrogen replacement therapy prescribed to control menopausal symptoms increases the risk of developing endometrial cancer by 2- to 20-fold, with an increasing risk correlating with the duration of use. Reproductive characteristics associated with an increased risk of endometrial cancer include nulliparity, infertility, early age of menarche, and late age of menopause. The estimated cumulative risk of developing endometrial cancer by age 70 is 54% for ...